Belantamab ELISA Kit|贝兰他单抗ELISA检测试剂盒(靶标：贝兰他单抗酶联免疫检测试剂盒)
- 货号：RB9TDX959018
- 价格：面议
- 点击：503
产品介绍
产品参数
| 应用 | ELISA |
|---|---|
| 检测方法 | Colorimetric |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| 回收率 | 80-120% |
| 样本类型 | Plasma, Serum |
| 检测类型 | Quantitative |
| 稳定性和储存 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 运输条件 | 2-8 ℃ |
| 登录号 | Q02223 |
| 背景信息 | Belantamab mafodotin also known as GSK2857916 is a humanized, IgG1 antibody-drug conjugate (ADC) that binds specifically to BCMA. The parent anti-BCMA antibody (GSK2857914) is produced in an afucosylated form and is conjugated to the microtubule polymerization inhibitor MMAF, via a protease-resistant maleimidocaproyl (mc) linker, to produce the GSK2857916 ADC molecule. Upon binding to the cell surface, GSK2857916 is rapidly internalized and active cytotoxic drug (cys-mcMMAF) is released inside the cell causing cell-cycle arrest and apoptosis. Furthermore, the afucosylation of GSK2857916 leads to enhanced binding to FcγRIIIa receptors on the surface of immune effector cells, recruitment of immune cells, and antibody-dependent cellular cytotoxicity and phagocytosis (ADCC and ADCP, respectively). This dual mechanism of action enables improved efficacy by targeting both dividing (via ADC) and non-dividing (via ADCC/ADCP) tumor cells. Recently, belantamab mafodotin was approved under the name BLENREP in the United States and European Union for the treatment of patients with relapsed or refractory multiple myeloma. |
| 别名 | 2857916, GSK2857916, J6M0, J6M0-mcMMAF, 2061894-48-0 |
| 备注 | For Research Use Only. |
相关产品:
